Associate Professor Usha Panchapakesan

BscMed MBBS ( Hons Class 1) Nephrologist PhD
Principal Research Fellow
Medicine, Northern Clinical School

Telephone +61 2 9926 4783

Map

Biographical details

Associate Professor Panchapakesan trained as a renal specialist and was awarded her Fellowship of the Royal Australasian College of Physicians in 2003. She has actively chosen a career in medical research over clinical medicine. In 2003 she commenced her PhD at the Kolling Institute of Medical Research, University of Sydney funded by the Jacquot Research Entry Scholarship and a National Health and Medical Research Council Scholarship. She was awarded her PhD in 2006. Her PhD studies resulted in several publications including a solicited review in Nature Clinical Practice – Nephrology. Based on her PhD studies, she was an invited speaker at the 2006 Kimmelstiel Meeting of Endocrinologists and Nephrologists. She subsequently received the prestigious Jacquot Fellowship for her postdoctoral studies and this was renewed for a second year of funding. She currently works as a Principal Reserach Fellow and supervises a PhD student and an Honours student after completing a Development Program for Research Higher Degree Supervision (University of Sydney). She leads her group in the area of novel therapeutics/drug repurposing in diabetic kidney disease.

Usha is also a Postgraduate Coordinator at the Northern Clinical School and a member of the Postgraduate Education Committee.

Research interests

Dr. U. Panchapakesan's research interests are in the renal complications of diabetes, an area of significant unmet need. Her expertise is in drug repurposing, ovel therapeutics and gene therapy to address diabetic kidney disease. Her reserach engages industry collaborations with view to translational outputs.

Teaching and supervision

Associate Professor Panchapakesan is passionate about medical education.She has engaged in teaching/examining in an inclusive sense since 1995 (high school work experience, undergraduate, graduate, higher research degree, junior doctors, physicians in training) in the form of lectures, tutorials, problem based learning, OSCEs, bedside/clinical, laboratory based not only through the Northern Clinical School, Royal North Shore Hospital but also across most of the medical schools in Sydney. She was awarded the Best Broblem Based Tutor (Northern Clinical School) in 2008 and continues to receive excellent feedback from medical students.

Current projects

1. The Role of Long Non Coding RNA in Diabetic Kidney Disease

2. Primary ciliopathy in Diabetic Kidney Disease

Selected grants

2012

  • The role of DPP4 inhibition in diabetic nephropathy independent of glycaemic control; Panchapakesan U; Bristol Myers Squibb/Research Support.

2011

  • Renal protection with SGLT2 inhibition; Pollock C, Forbes J, Panchapakesan U; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • The Role of Toll-like Receptors in Diabetic Nephropathy; Chadban S, Pollock C, Wu H, Panchapakesan U; National Health and Medical Research Council (NHMRC)/Project Grants.

2006

  • The role of endothelial stem cells and Erthropoeitin in vascular disease in patients with Mellitus and/or chronic kidney disease; Panchapakesan U; Diabetes Australia/Diabetes Research Grant Program.
  • The role of endothelial stem cells and atorvastin in vascular disease observed in patients with diabetes and/or chronic kidney disease; Panchapakesan U; Royal Australasian College of Physicians/Jacquot Research Establishment Award.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Pollock, C., Panchapakesan, U. (2018). Drug repurposing in kidney disease. Kidney International, 94(1), 40-48. [More Information]
  • Panchapakesan, U., Pollock, C. (2018). The role of toll-like receptors in diabetic kidney disease. Current Opinion In Nephrology And Hypertension, 27(1), 30-34. [More Information]
  • Panchapakesan, U., Pollock, C. (2016). Long non-coding RNAs-towards precision medicine in diabetic kidney disease? Clinical Science, 130(18), 1599-1602. [More Information]
  • Gallo, L., Ward, M., Fotheringham, A., Zhuang, A., Borg, D., Flemming, N., Harvie, B., Kinneally, T., Yeh, S., McCarthy, D., Pollock, C., Panchapakesan, U., et al (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports, 6, 1-16. [More Information]
  • Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., Panchapakesan, U. (2016). Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology, 21(5), 423-431. [More Information]
  • Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., Panchapakesan, U. (2015). Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin. PloS One, 10(10), 1-15. [More Information]
  • Salheen, S., Panchapakesan, U., Pollock, C., Woodman, O. (2015). The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose. PloS One, 10(11), 1-15. [More Information]
  • Salheen, S., Panchapakesan, U., Pollock, C., Woodman, O. (2015). The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacological Research, 94, 26-33. [More Information]
  • Panchapakesan, U., Pollock, C. (2015). The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease. Frontiers in Immunology, 6, 1-5. [More Information]
  • Panchapakesan, U., Pollock, C. (2014). DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes, 63(6), 1829-1830. [More Information]
  • Gangadharan Komala, M., Gross, S., Mudaliar, H., Huang, C., Pegg, K., Mather, A., Shen, S., Pollock, C., Panchapakesan, U. (2014). Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice. PloS One, 9(11), 1-12. [More Information]
  • Ma, J., Wu, H., Zhao, C., Panchapakesan, U., Pollock, C., Chadban, S. (2014). Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. International Journal of Clinical and Experimental Pathology, 7(2), 481-495.
  • Mudaliar, H., Pollock, C., Panchapakesan, U. (2014). Role of toll-like receptors in diabetic nephropathy. Clinical Science, 126(10), 685-694. [More Information]
  • Mudaliar, H., Pollock, C., Ma, J., Wu, H., Chadban, S., Panchapakesan, U. (2014). The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. PloS One, 9(10), 1-14. [More Information]
  • Ma, J., Chadban, S., Zhao, C., Chen, X., Kwan, T., Panchapakesan, U., Pollock, C., Wu, H. (2014). TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PloS One, 9(5), 1-12. [More Information]
  • Panchapakesan, U., Pegg, K., Gross, S., Gangadharan Komala, M., Mudaliar, H., Forbes, J., Pollock, C., Mather, A. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy? PloS One, 8(2), 1-8. [More Information]
  • Panchapakesan, U., Mather, A., Pollock, C. (2013). Role of glp-1 and dpp-4 in diabetic nephropathy and cardiovascular disease. Clinical Science, 124(1), 17-26. [More Information]
  • Gangadharan Komala, M., Panchapakesan, U., Pollock, C., Mather, A. (2013). Sodium glucose cotransporter 2 and the diabetic kidney. Current Opinion In Nephrology And Hypertension, 22(1), 113-119. [More Information]
  • Mudaliar, H., Pollock, C., Gangadharan Komala, M., Chadban, S., Wu, H., Panchapakesan, U. (2013). The role of toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. AJP: Renal Physiology (Online), 305(2), F143-F154. [More Information]
  • Panchapakesan, U., Pollock, C. (2012). Novel Treatments in Diabetic Nephropathy. Current Hypertension Reviews, 8(1), 71-78. [More Information]
  • Wong, M., Panchapakesan, U., Qi, W., Silva, D., Chen, X., Pollock, C. (2011). Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-B1. American Journal of Physiology: Renal Physiology, 301(1), F84-F93. [More Information]
  • Panchapakesan, U., Pollock, C., Saad, S. (2011). Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology, 38(2), 84-88. [More Information]
  • Wu, H., Ma, J., Wang, P., Corpuz, T., Panchapakesan, U., Wyburn, K., Chadban, S. (2010). HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. Journal of the American Society of Nephrology, 21(11), 1878-1890. [More Information]
  • Panchapakesan, U., Pollock, C., Saad, S. (2009). Review Article: Importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology, 14(3), 298-301. [More Information]
  • Panchapakesan, U., Sumual, S., Pollock, C. (2007). Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). International Journal of Nanomedicine, 2(1), 33-38. [More Information]
  • Panchapakesan, U., Chen, X., Pollock, C. (2005). Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection. Nature Clinical Practice. Nephrology, 1(1), 33-43. [More Information]
  • Panchapakesan, U., Sumual, S., Pollock, C., Chen, X. (2005). PPAR gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology: Renal Physiology, 289(5), F1153-F1158. [More Information]
  • Panchapakesan, U., Pollock, C., Chen, X. (2004). The effect of high glucose and PPAR- agonists on PPAR- expression and function in HK-2 cells. American Journal of Physiology: Renal Physiology, 287(3 56-3), F528-F534. [More Information]
  • Panchapakesan, U., Pollock, C., Chen, X. (2004). The Effect Of High Glucose And Ppar-Gamma Agonists On Ppar-Gamma Expression And Function In Hk-2 Cells. American Journal of Physiology: Renal Physiology, 287(3), F528-F534. [More Information]
  • Panchapakesan, U., Austin, S., Shafransky, A., Lawrence, J., Savdie, E. (2003). Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Internal Medicine Journal, 33, 468-471. [More Information]
  • Panchapakesan, U., Austin, S., Shafransky, A., Lawrence, J., Savdie, E. (2003). Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Internal Medicine Journal, 33(9-10), 468-471. [More Information]

2018

  • Pollock, C., Panchapakesan, U. (2018). Drug repurposing in kidney disease. Kidney International, 94(1), 40-48. [More Information]
  • Panchapakesan, U., Pollock, C. (2018). The role of toll-like receptors in diabetic kidney disease. Current Opinion In Nephrology And Hypertension, 27(1), 30-34. [More Information]

2016

  • Panchapakesan, U., Pollock, C. (2016). Long non-coding RNAs-towards precision medicine in diabetic kidney disease? Clinical Science, 130(18), 1599-1602. [More Information]
  • Gallo, L., Ward, M., Fotheringham, A., Zhuang, A., Borg, D., Flemming, N., Harvie, B., Kinneally, T., Yeh, S., McCarthy, D., Pollock, C., Panchapakesan, U., et al (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports, 6, 1-16. [More Information]
  • Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., Panchapakesan, U. (2016). Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology, 21(5), 423-431. [More Information]

2015

  • Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., Panchapakesan, U. (2015). Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin. PloS One, 10(10), 1-15. [More Information]
  • Salheen, S., Panchapakesan, U., Pollock, C., Woodman, O. (2015). The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose. PloS One, 10(11), 1-15. [More Information]
  • Salheen, S., Panchapakesan, U., Pollock, C., Woodman, O. (2015). The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacological Research, 94, 26-33. [More Information]
  • Panchapakesan, U., Pollock, C. (2015). The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease. Frontiers in Immunology, 6, 1-5. [More Information]

2014

  • Panchapakesan, U., Pollock, C. (2014). DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes, 63(6), 1829-1830. [More Information]
  • Gangadharan Komala, M., Gross, S., Mudaliar, H., Huang, C., Pegg, K., Mather, A., Shen, S., Pollock, C., Panchapakesan, U. (2014). Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice. PloS One, 9(11), 1-12. [More Information]
  • Ma, J., Wu, H., Zhao, C., Panchapakesan, U., Pollock, C., Chadban, S. (2014). Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. International Journal of Clinical and Experimental Pathology, 7(2), 481-495.
  • Mudaliar, H., Pollock, C., Panchapakesan, U. (2014). Role of toll-like receptors in diabetic nephropathy. Clinical Science, 126(10), 685-694. [More Information]
  • Mudaliar, H., Pollock, C., Ma, J., Wu, H., Chadban, S., Panchapakesan, U. (2014). The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. PloS One, 9(10), 1-14. [More Information]
  • Ma, J., Chadban, S., Zhao, C., Chen, X., Kwan, T., Panchapakesan, U., Pollock, C., Wu, H. (2014). TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PloS One, 9(5), 1-12. [More Information]

2013

  • Panchapakesan, U., Pegg, K., Gross, S., Gangadharan Komala, M., Mudaliar, H., Forbes, J., Pollock, C., Mather, A. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy? PloS One, 8(2), 1-8. [More Information]
  • Panchapakesan, U., Mather, A., Pollock, C. (2013). Role of glp-1 and dpp-4 in diabetic nephropathy and cardiovascular disease. Clinical Science, 124(1), 17-26. [More Information]
  • Gangadharan Komala, M., Panchapakesan, U., Pollock, C., Mather, A. (2013). Sodium glucose cotransporter 2 and the diabetic kidney. Current Opinion In Nephrology And Hypertension, 22(1), 113-119. [More Information]
  • Mudaliar, H., Pollock, C., Gangadharan Komala, M., Chadban, S., Wu, H., Panchapakesan, U. (2013). The role of toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. AJP: Renal Physiology (Online), 305(2), F143-F154. [More Information]

2012

  • Panchapakesan, U., Pollock, C. (2012). Novel Treatments in Diabetic Nephropathy. Current Hypertension Reviews, 8(1), 71-78. [More Information]

2011

  • Wong, M., Panchapakesan, U., Qi, W., Silva, D., Chen, X., Pollock, C. (2011). Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-B1. American Journal of Physiology: Renal Physiology, 301(1), F84-F93. [More Information]
  • Panchapakesan, U., Pollock, C., Saad, S. (2011). Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology, 38(2), 84-88. [More Information]

2010

  • Wu, H., Ma, J., Wang, P., Corpuz, T., Panchapakesan, U., Wyburn, K., Chadban, S. (2010). HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. Journal of the American Society of Nephrology, 21(11), 1878-1890. [More Information]

2009

  • Panchapakesan, U., Pollock, C., Saad, S. (2009). Review Article: Importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology, 14(3), 298-301. [More Information]

2007

  • Panchapakesan, U., Sumual, S., Pollock, C. (2007). Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). International Journal of Nanomedicine, 2(1), 33-38. [More Information]

2005

  • Panchapakesan, U., Chen, X., Pollock, C. (2005). Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection. Nature Clinical Practice. Nephrology, 1(1), 33-43. [More Information]
  • Panchapakesan, U., Sumual, S., Pollock, C., Chen, X. (2005). PPAR gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology: Renal Physiology, 289(5), F1153-F1158. [More Information]

2004

  • Panchapakesan, U., Pollock, C., Chen, X. (2004). The effect of high glucose and PPAR- agonists on PPAR- expression and function in HK-2 cells. American Journal of Physiology: Renal Physiology, 287(3 56-3), F528-F534. [More Information]
  • Panchapakesan, U., Pollock, C., Chen, X. (2004). The Effect Of High Glucose And Ppar-Gamma Agonists On Ppar-Gamma Expression And Function In Hk-2 Cells. American Journal of Physiology: Renal Physiology, 287(3), F528-F534. [More Information]

2003

  • Panchapakesan, U., Austin, S., Shafransky, A., Lawrence, J., Savdie, E. (2003). Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Internal Medicine Journal, 33, 468-471. [More Information]
  • Panchapakesan, U., Austin, S., Shafransky, A., Lawrence, J., Savdie, E. (2003). Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Internal Medicine Journal, 33(9-10), 468-471. [More Information]

To update your profile click here. For support on your academic profile contact .